Assessment of Days Alive Out of Hospital as a Possible End Point in Trials of Stroke Prevention for Atrial Fibrillation: A ROCKET AF Analysis.
Josephine HarringtonAnne S HellkampKenneth W MahaffeyGuenter BreithardtJonathan L HalperinGraeme J HankeyRichard C BeckerChristopher C NesselScott D BerkowitzKeith A A FoxDaniel E SingerShaun G GoodmanManesh R PatelJonathan P PicciniPublished in: Journal of the American Heart Association (2024)
DAOH did not identify a treatment difference between patients randomized to rivaroxaban versus warfarin. This may be driven in part by the low overall event rates in atrial fibrillation anticoagulation trials, which leads to substantial left skew in measures of DAOH.
Keyphrases
- atrial fibrillation
- oral anticoagulants
- catheter ablation
- left atrial
- direct oral anticoagulants
- left atrial appendage
- end stage renal disease
- heart failure
- ejection fraction
- newly diagnosed
- percutaneous coronary intervention
- healthcare
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- randomized controlled trial
- double blind
- open label
- clinical trial
- patient reported outcomes
- pulmonary embolism
- phase ii
- brain injury
- placebo controlled
- patient reported
- smoking cessation
- mitral valve
- replacement therapy
- subarachnoid hemorrhage
- cerebral ischemia